Tag: Financing

The 268-unit Class A multifamily community in Chesapeake’s Greenbrier submarket is backed by long-term capital from Bonaventure’s high-net-worth investor network with long-term HUD financing for a lasting community investment

SAN JOSE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today provided an update regarding its $995 million term loan credit facility (the “Term Loan”). On June 5, 2026, S&P Global Ratings upgraded the Company’s issuer credit rating to BB- from B+, with a positive outlook. As previously disclosed on May 28, 2026, the Company recently entered into an amendment of its credit agreement, providing for a 25 basis point decrease in pricing, with an additional 25 basis point reduction at the time of a ratings upgrade by either major agency. As a result of the credit rating upgrade, pricing on the Term Loan has now declined to Secured Overnight Financing Rate (“SOFR”) plus 1.75%.

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai^® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company’s financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company’s discretion to support business development and capitalize on market opportunities.

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.